#South Korea #Seoul #Hugel Inc #Hyaluronic Acid #Botulinum Toxin

Hugel Achieves Record Net Sales in H1 2025

In an impressive showcase of its rapid growth and expansion, Hugel Inc., the prominent medical aesthetics company based in South Korea, reported record net sales that surpassed KRW200 billion for the first half of 2025. This significant milestone reflects not just the robustness of Hugel's core products but also the company’s strategic initiatives aimed at broadening its market presence internationally.

Hugel released its consolidated financial results for Q2 2025 on August 6, revealing a net sales figure of KRW110.3 billion and an operating profit of KRW56.7 billion. These numbers represent a remarkable uptick compared to the same period last year, with increases of 15.5% and 33.6%, respectively. Moreover, the company reported a net income of KRW38.2 billion, which is a 3.3% rise year-on-year, marking Q2 2025 as one of the most successful quarters in the company’s history.

Factors Behind the Success

The success during the April-June period can be attributed to a variety of factors, notably the surging overseas sales of its flagship products, including botulinum toxin and hyaluronic acid fillers. Sales from international markets, which hit KRW69.8 billion, accounted for 63% of the total net sales for the quarter, showcasing the ongoing demand for Hugel's products on a global scale.

As the first South Korean company to gain approval in the three largest botulinum toxin markets worldwide—namely the United States, China, and Europe—Hugel stands at the forefront of the medical aesthetics sector. Export strength was particularly evident in Q2, where a staggering 73% of the sales from botulinum toxin and hyaluronic acid fillers were attributed to overseas markets.

Product Performance

Diving deeper into the product specifics, the botulinum toxin, known domestically as Botulax and internationally branded as Letybo, generated net sales reaching KRW61.2 billion in Q2, reflecting a healthy 20% increase year-on-year. This growth was bolstered by additional shipments to the US following its official launch in March and by steady demand across Asia-Pacific markets.

On the other hand, the hyaluronic acid filler segment, comprising the locally branded THE CHAEUM and BYRYZN Skin Booster HA, achieved net sales of KRW34.1 billion during the quarter. This reflects strong market performance in both the Asia-Pacific and European regions. Additionally, the company’s cosmetics lines, which include brands like WELLAGE and BYRYZN BR, saw remarkable growth, with a 104.5% increase in sales amounting to KRW13.6 billion.

Future Prospects

Looking forward, Hugel is poised to continue this upward trajectory by enhancing its market penetration in the US, capitalizing on the quality and competitiveness of its toxin products. The company remains focused on bolstering its market leadership in China while also expanding into Middle Eastern and emerging markets.

As a pioneer in the medical aesthetics industry, established in 2001, Hugel has cemented itself as a key player in the field of injectable treatments for skin rejuvenation, offering a diverse range of products including botulinum toxins and hyaluronic acid fillers. With its regulatory approvals in three of the world's largest markets, the company has built a robust presence across approximately 70 countries and operates nine subsidiaries globally. Hugel is strategically positioned for sustainable growth and aims to uphold its commitment to quality and safety through continuous product innovation and industry engagement.

In summary, Hugel’s record sales and operating profits in H1 2025 not only underscore its successful business strategies but also highlight its potential for future growth in the dynamic landscape of the global medical aesthetics market.